<DOC>
	<DOCNO>NCT00126204</DOCNO>
	<brief_summary>The durability endovascular aneurysm repair ( EVAR ) limit development endoleaks may secondary progressive aortic degeneration matrix metalloproteases ( MMP ) . Doxycycline know inhibitor MMP family enzymes aneurysms . The investigator propose randomize , control trial adjuvant doxycycline therapy EVAR determine effect re-intervention , aneurysm shrinkage serum marker aneurysmal degeneration .</brief_summary>
	<brief_title>Adjunctive Treatment With Doxycycline Enhance Durability Endovascular Aortic Aneurysm Repair</brief_title>
	<detailed_description>Patients consent enrolled time clinic visit admission hospital plan EVAR , accordance institutional review board guideline . Demographic , risk factor medication regimen data obtain patient 's clinical chart . Patients randomized doxycycline therapy ( 100 mg take twice daily ) placebo . The patient receive first dose study medication day follow surgery , continue study therapy 6 month . Plasma serum obtain time enrollment ( baseline ) , post-operative follow-up visit study outline . Aliquots store -80ºC assay . Measurements circulate marker perform commercially available assay plasma MMP-9 ( R &amp; D Systems , Minneapolis , MN ) , serum IL-6 ( R &amp; D Systems ) , IL-8 ( R &amp; D Systems ) , IFN-gamma ( R &amp; D Systems ) , CRP ( Bio-Check , Burlingame , CA ) Data collect pre-operative post-operative CT scan regard maximal aneurysm diameter transverse neck diameter 5 mm , 10 mm 15 mm takeoff low renal artery . All document endoleaks clinical type record , re-intervention related graft aneurysm . The primary end-points study relate aneurysm measurement increase decrease diameter measurement aorta 2 mm 2 consecutive CT scan change 5 mm single scan . Of circulate marker , additional primary endpoint 50 % reduction baseline MMP-9 endografting . Secondary endpoint significant reduction baseline circulate IL-6 , IL-8 , IFN-γ , CRP . An priori power analysis indicate 6 month , reduction circulate level marker 50 % detect β-error less 0.1 α-error less 0.05 .</detailed_description>
	<mesh_term>Aneurysm</mesh_term>
	<mesh_term>Aortic Aneurysm</mesh_term>
	<mesh_term>Doxycycline</mesh_term>
	<criteria>Presence abdominal aortic aneurysm ( AAA ) maximum diameter &gt; = 4.5 cm Planned aneurysm exclusion endoluminal stent graft ( brand ) Known malignancy include prostate cancer history cancer recurrence last 5 year . Hypersensitivity doxycycline component Pregnancy Ruptured AAA Extension cover portion graft renal artery Previous endoluminal aneurysm repair</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>endoleak</keyword>
	<keyword>doxycycline</keyword>
	<keyword>matrix metalloproteinase</keyword>
	<keyword>inflammation</keyword>
	<keyword>endograft</keyword>
	<keyword>circulate marker</keyword>
</DOC>